Glucagon-like peptide-1 receptor agonists, also known as GLP-1 agonists and GLP-1RAs, are a class of medications that activate the GLP-1 receptor, causing reduced blood sugar, reduced appetite, and reduced energy intake.
To investigate the genetic basis of this variability, here we conduct a genome-wide association study of self-reported weight loss and treatment-related side effects in 27,885 people following GLP1 receptor agonist therapy.
Although GLP-1 agonists have side effects, the weight loss benefits may outweigh their risks.
Common Side Effects of GLP-1 Agonists. GLP-1 receptor agonists, such as semaglutide and tirzepatide, are effective medications for managing obesity and type 2 diabetes.
The most common side effects (nausea, vomiting, and diarrhea) are usually mild and occur in the first few weeks of treatment, reducing over time. Because of the difficulties many people face in maintaining weight loss, lifelong treatment may be needed.
Learn about effectiveness, side effects, and more.One of these methods is weight loss injections. These GLP-receptor agonist injections have gained popularity as a potential solution for those seeking safe, effective, and convenient ways to manage their weight.
The weight loss effect is a combination of fat mass and lean muscle mass due to severe and chronic low energy intake. Preventing muscle loss with Semaglutide should focus on resistance exercise training and combination with sufficient dietary protein to mitigate the loss of muscle.
GLP-1 Receptor Agonist: Danuglipron mimics the effects of GLP-1 by activating GLP-1 receptors in the body. This can lead to several effects that promote weight loss
Paper published in Nature on genetic predictors of GLP-1 receptor agonists. This study confirms what I have observed in clinical practice and helps explain why these drugs work better in some individuals and why side effects are more common in others.
